/
DCF Valuation
Base-case fair value
$0.58
Intrinsic $0.78 · 25% MOS
Base-case summary
Our base-case DCF for Elite Pharmaceuticals Inc (ELTP) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 43.2% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $17M in trailing free cash flow, this produces an intrinsic value of $0.78 per share. A 25% safety margin gives a fair value of $0.58.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$17M
Cash & equivalents
$22M
Total debt
$4M
Shares outstanding
1.1B